Metastatic Type II Papillary Renal Cell Carcinoma With Recurrent Complete Responses to Sunitinib: A Case Report With a Literature Review

Papillary renal cell carcinoma (PRCC) is a less common subtype of kidney cancer and is typically more resistant to systemic treatments. This report describes a patient with metastatic type II PRCC who experienced two complete responses (CR) to the tyrosine kinase inhibitor (TKI) sunitinib. The patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Ashour, Bayan H, Azam, Faisal, Ibnshamsah, Fahad, Alrowais, Fahad, Al-Garni, Ayed, Al-Shamsi, Humaid O, Bukhari, Nedal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246320/
https://www.ncbi.nlm.nih.gov/pubmed/35800817
http://dx.doi.org/10.7759/cureus.25541
Descripción
Sumario:Papillary renal cell carcinoma (PRCC) is a less common subtype of kidney cancer and is typically more resistant to systemic treatments. This report describes a patient with metastatic type II PRCC who experienced two complete responses (CR) to the tyrosine kinase inhibitor (TKI) sunitinib. The patient remains on sunitinib with durable control of the disease. To the best of our knowledge, this is the first case of metastatic type II PRCC with CR to sunitinib.

Ejemplares similares